Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Mechanism of action of daratumumab

Niels van de Donk • 9 Jun 2016
EHA 2016
Multiple Myeloma Antibodies Daratumumab

Niels van de Donk, MD, PhD from the University Medical Center, Amsterdam, Netherlands discusses the mechanism of action of daratumumab at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Daratumumab induces antibody-dependent cellular cytotoxicity (ACC), antibody-dependent cellular cell-mediated phagocytosis (ADCP) as well as complement-dependent cytotoxicity (CDC). Dr van de Donk further explains that daratumumab has been shown to eliminate regulatory T-cells, regulatory B-cells and myeloid-derived suppressor cells. The elimination of various immune suppressors may help the T-cell system to recover.

More from Niels van de Donk

4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
2:42
Iberdomide plus dexamethasone for heavily pretreated multiple myeloma
Niels van de Donk • 13 Dec 2021
3:03
The future of CAR-T therapy for multiple myeloma
Niels van de Donk • 13 Dec 2021
1:45
Mechanisms of action of CD38 antibodies in myeloma
Niels van de Donk • 13 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals